| For Practicing Oncologists |
  See all
 | Articles: Myeloproliferative Dz |
Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies
Cancer, 06/03/08
Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC)
Annals of Oncology, 06/02/08
Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: Differential diagnosis between refractory anemia and aplastic anemia
Pathology International, 06/02/08
 | | Sponsor |
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
Annals of Oncology, 06/02/08
A Role for JAK2 Mutations in Myeloproliferative Diseases
Annual Review of Medicine, 05/28/08
A case of essential thrombocythemia in an 8-year-old boy
Pediatric Hematology and Oncology, 05/27/08
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal
Leukemia, 05/23/08
The Emperors New Clothes or the Current Practice of Clinical Trials for Multiple Myeloma in the USA
Cancer Investigation, 05/22/08
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up
British Journal of Haematology, 05/21/08
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy
British Journal of Haematology, 05/21/08
|
|
Receive daily email updates on Myeloproliferative Dz
|
|
Indexed Journals: Journal of Clinical Oncology, Cancer Research, Annals Oncology
more...
|
144 Available Pages
 |
 |
| Sponsor |
|
|
| Read a Different Specialty |
 |
|
|
|
|
| Profession Index |
|
|
|
|
|
|
 |
| Sponsor |
 |
| Sponsor |
|
